» Articles » PMID: 11779872

Functional Cooperation Among Ras, STAT5, and Phosphatidylinositol 3-kinase is Required for Full Oncogenic Activities of BCR/ABL in K562 Cells

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2002 Jan 10
PMID 11779872
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

BCR/ABL tyrosine kinase generated from the chromosomal translocation t(9;22) causes chronic myelogenous leukemia and acute lymphoblastic leukemia. To examine the roles of BCR/ABL-activated individual signaling molecules and their cooperation in leukemogenesis, we inducibly expressed a dominant negative (DN) form of Ras, phosphatidylinositol 3-kinase, and STAT5 alone or in combination in p210 BCR/ABL-positive K562 cells. The inducibly expressed DN Ras (N17), STAT5 (694F), and DN phosphatidylinositol 3-kinase (Delta p85) inhibited the growth by 90, 55, and 40%, respectively. During the growth inhibition, the expression of cyclin D2 and cyclin D3 was suppressed by N17, 694F, or Delta p85; that of cyclin E by N17; and that of cyclin A by Delta p85. In addition, N17 induced apoptosis in a small proportion of K562, whereas 694F and Delta p85 were hardly effective. In contrast, coexpression of two DN mutants in any combinations induced severe apoptosis. During these cultures, the expression of Bcl-2 was suppressed by N17, 694F, or Delta p85, and that of Bcl-XL by N17. Furthermore, although K562 was resistant to interferon-alpha- and dexamethasone-induced apoptosis, disruption of one pathway by N17, 694F, or Delta p85 sensitized K562 to these reagents. These results suggested that cooperation among these molecules is required for full leukemogenic activities of BCR/ABL.

Citing Articles

FL118 Is a Potent Therapeutic Agent against Chronic Myeloid Leukemia Resistant to BCR-ABL Inhibitors through Targeting RNA Helicase DDX5.

Takeda K, Ohta S, Nagao M, Kobayashi E, Tago K, Funakoshi-Tago M Int J Mol Sci. 2024; 25(7).

PMID: 38612503 PMC: 11011477. DOI: 10.3390/ijms25073693.


Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.

Mali R, Zhang Q, DeFilippis R, Cavazos A, Kuruvilla V, Raman J Haematologica. 2020; 106(4):1034-1046.

PMID: 32414851 PMC: 8017817. DOI: 10.3324/haematol.2019.244020.


Feasibility of tumor‑derived exosome enrichment in the onco‑hematology leukemic model of chronic myeloid leukemia.

Bernardi S, Foroni C, Zanaglio C, Re F, Polverelli N, Turra A Int J Mol Med. 2019; 44(6):2133-2144.

PMID: 31638195 PMC: 6844640. DOI: 10.3892/ijmm.2019.4372.


Altered intracellular signaling by imatinib increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells.

Hirao T, Yamaguchi M, Kikuya M, Chibana H, Ito K, Aoki S Cancer Sci. 2017; 109(1):121-131.

PMID: 29121435 PMC: 5765287. DOI: 10.1111/cas.13442.


Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells.

Giudice V, Ricci P, Marino L, Rocco M, Villani G, Langella M Transl Med UniSa. 2016; 15:22-33.

PMID: 27896224 PMC: 5120747.